

Giovanni Barillari - *Curriculum Vitae et Studiorum*

(aggiornato al 23 marzo 2024)

Informazioni personali

Nome: BARILLARI, Giovanni

Indirizzo: Dipartimento di Scienze Cliniche e Medicina Traslazionale, Università degli Studi di Roma "Tor Vergata", via Montpellier 1, 00133 Roma

Telefono: 39-06-72596510

E-mail: barillar@uniroma2.it

Titoli di studio

1983: Laurea in Medicina e Chirurgia, Università di Roma "Sapienza", voto 110/110 e lode.

1987: Specializzazione in Patologia Generale, Università di Roma "Sapienza", voto 70/70 e lode.

1989: Corso di Perfezionamento in Metodologia del DNA Ricombinante, Foundation for Advanced Education in Sciences (FAES), National Institutes of Health (NIH), Bethesda (MD), USA.

1989: Corso di Perfezionamento in Biologia Cellulare, FAES, USA.

1990: Corso di Perfezionamento in Metodi di Ricerca sul DNA, FAES, USA.

1991: Corso di Perfezionamento in Tecnologia di Amplificazione ed Ibridazione Molecolare, FAES, USA.

Madrelingua: italiano

Altre lingue: inglese. Livello di conoscenza: C2 (proficiency), come attestato dalla certificazione TOEFL conseguita presso la "George Washington University" di Washington (DC, Stati Uniti d'America).

Cronologia d'impiego

2006-*data odierna*: Professore Ordinario di Patologia Clinica, Facoltà di Medicina e Chirurgia, Università degli Studi di Roma "Tor Vergata".

2000-2006: Professore Associato di Patologia Generale, Facoltà di Medicina e Chirurgia, Università degli Studi di Roma "Tor Vergata".

1993-2000: Ricercatore Universitario presso il Dipartimento di Medicina Sperimentale, Università degli Studi di Roma "Tor Vergata".

1988-1993: ricercatore ospite del Laboratorio di Biologia della Cellula Tumorale, National Cancer Institute, NIH, Bethesda (MD), USA.

1987-1988: borsista presso il Dipartimento di Medicina Sperimentale, Facoltà di Medicina e Chirurgia, Università degli Studi di Roma "Tor Vergata".

1983-1987: borsista presso l'Istituto di Patologia Generale, Facoltà di Medicina e Chirurgia, Università degli Studi di Roma "Sapienza".

Attività didattica corrente (anno accademico 2023-2024)

Università degli Studi di Roma "Tor Vergata", Facoltà di Medicina e Chirurgia

Corsi di Laurea Magistrale. Titolare dell'insegnamento "Patologia Clinica" ed affidatario dell'insegnamento "Patologia Generale" presso il Corso di Laurea in Odontoiatria e Protesi Dentaria. Co-titolare dell'insegnamento "Patologia Clinica" presso il Corso di Laurea in Medicina e Chirurgia. Titolare dell'insegnamento "Patologia Clinica" presso il Corso di Laurea in Pharmacy.

Corsi di Laurea Sanitaria Triennale. Titolare dell'insegnamento "Patologia Clinica" presso il Corso di Laurea in Igienista Dentale. Titolare dell'insegnamento "Patologia Clinica" presso il Corso di Laurea in Tecniche di Fisiopatologia Cardiocircolatoria e Perfusione Cardiovascolare.

Scuole di Specializzazione. Docente presso la Scuole di Specializzazione in "Patologia e Biochimica Clinica", "Ematologia", "Endocrinologia e Malattie del Metabolismo", "Igiene e Medicina Preventiva", "Malattie dell'Apparato Respiratorio", "Medicina Fisica e Riabilitativa", "Medicina Interna", "Anatomia Patologica" e "Oncologia".

Catholic University "Zoja e Këshillit të Mirë", School of Medicine, Tirane, Albany. Insegnamento "Patologia Clinica" e "Patologia Generale" presso il Corso di Laurea in Odontoiatria e Protesi Dentaria.

International University of Health and Medical Sciences "UniCamillus", Rome, Italy. Insegnamento "Patologia Clinica" presso i Corsi di Laurea in Medicina e Chirurgia e in Odontoiatria e Protesi Dentaria.

Incarichi scientifici

Componente del Comitato Scientifico-Strategico del Consorzio interuniversitario AlmaLaurea.

Revisore di progetti di ricerca scientifica presentati al Ministero della Salute oppure al Ministero dell'Università e della Ricerca. In tale contesto, è iscritto nel registro degli esperti scientifici indipendenti, italiani e stranieri (*Register of Expert Peer Reviewers for Italian Scientific Evaluation, REPRISE*), istituito presso il Ministero dell'Università e della Ricerca.

Revisore di articoli scientifici presso riviste internazionali con ISSN quali, ad esempio, *Cancers, Current Oncology, International Journal of Molecular Sciences, Biomedicines* ed altri.

Membro del Comitato Editoriale di *International Journal of Molecular Sciences* (casa editrice MDPI -Multidisciplinary Digital Publishing Institute, Basilea, Svizzera).

Socio Ordinario dell'*Accademia Medica di Roma* (Roma, Italia).

Incarichi istituzionali

Maggio 2023- tempo presente. Coordinatore della Commissione per l'Assicurazione della Qualità del Dipartimento di Scienze Cliniche e Medicina Traslazionale dell'Università degli Studi di Roma "Tor Vergata"

Maggio 2023 – tempo presente. Coordinatore della Commissione Didattica del Dipartimento di Scienze Cliniche e Medicina Traslazionale dell'Università degli Studi di Roma "Tor Vergata"

2020 – 2023: componente dell'Osservatorio sulla Didattica, Facoltà di Medicina e Chirurgia, Università degli Studi di Roma "Tor Vergata".

Dicembre 2013-novembre 2019. Prorettore delegato alla Didattica d'Ateneo, Università degli Studi di Roma "Tor Vergata".

2009-2013. Presidente della Commissione Didattica della Facoltà di Medicina e Chirurgia, Università degli Studi di Roma "Tor Vergata".

Attività Scientifica

L'attività di ricerca è concentrata sullo studio: i) della formazione di nuovi vasi sanguigni e linfatici associata alla progressione neoplastica; ii) dei meccanismi alla base dell'invasività neoplastica e della metastatizzazione; iii) degli effetti oncogeni di proteine virali; iv) dei marcatori diagnostici e prognostici di neoplasia; e v) degli effetti antitumorali degli inibitori delle proteasi.

Pubblicazioni “*peer-reviewed*” prodotte su giornali con ISSN = 114; H Index = 34 (*fonte WEB of SCIENCE*); Numero totale di citazioni = 6071 (*fonte WEB of SCIENCE*)

Elenco delle pubblicazioni prodotte

1. Carrano R, Grande M, Leti Maggio E, Zucca C, Bei R, Palumbo C, Focaccetti C, Nardozi D, Lucarini V, Angiolini V, Mancini P, Barberini F, Barillari G, Cifaldi L, Masuelli L, Benvenuto M, Bei R. Dietary polyphenols effects on focal adhesion plaques in the course of cancer cells invasiveness. *Biomedicines* 2024, 12(3), 482 (review); doi: <https://doi.org/10.3390/biomedicines12030482>.
2. Pomella S, Cassandri M, D'Archivio L, Porrizzo A, Cossetti C, Phelps D, Perrone C, Pezzella M, Cardinale A, Wachtel M, Aloisi S, Milewski D, Colletti M, Sreenivas P, Walters ZS, Barillari G, Di Giannatale A, Milano GM, De Stefanis C, Alaggio R, Rodriguez-Rodriguez S, Carlesso N, Vakoc CR, Velardi E, Schafer BW, Guccione E, Gatz SA, Wasti A, Yohe M, Ignatius M, Quintarelli C, Shipley J, Miele L, Khan J, Houghton PJ, Marampon F, Gryder BE, De Angelis B, Locatelli F, Rota R. MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57^{Kip2} targeting. *Nat Commun.* 2023 Dec 15;14(1): 8373. doi: 10.1038/s41467-023-44130-0. PMID: 38102140; PMCID: PMC10724275.
3. Cifaldi L, Melaiu O, Giovannoni R, Benvenuto M, Focaccetti C, Nardozi D, Barillari G, Bei R. DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy. *Front Immunol* 2023; 14: 1197053. doi: 10.3389/fimmu.2023.1197053. PMID: 37359555 (Perspective review).
4. Benvenuto M, Angiolini V, Focaccetti C, Nardozi D, Palumbo C, Carrano R, Rufini A, Barillari G, Tundo GR, Bei R. Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo. *BIOLOGY DIRECT* 2023; 18(1): 17. doi 10.1186/s13062-023-00374-w (article).
5. Pomella S, Cassandri M, Melaiu O, Marampon F, Gargari M, Campanella V, Rota R, Barillari G. DNA damage response gene signature as potential treatment markers for oral squamous cell carcinoma. *Int J Mol Sci.* 2023 Jan 31;24(3):2673. doi: 10.3390/ijms24032673 (article, PMID: 36768994).
6. Melaiu O, Vanni G, Portarena I, Pistolese CA, Anemona L, Pomella S, Bei R, Buonomo OC, Roselli M, Mauriello A, Barillari G. The combination of immune checkpoint blockade with tumor vessel normalization as a promising therapeutic strategy for breast cancer: an overview of preclinical and clinical studies. *Int. J. Mol. Sci.* 2023, 24(4), 3226; <https://doi.org/10.3390/ijms24043226> (Review).
7. Rota R, Perrone C, Pomella S, Cassandri M, Pezzella M, Giuliani S, Gasperi T, Porrizzo A, Alisi A, Pastore A, Codenotti S, Fanzani A, Barillari G, Conti LA, De Angelis B, Quintarelli C, Mariottini P, Locatelli F, Marampon F, Cervelli M. Spermine oxidase induces DNA damage and sensitizes Fusion Negative Rhabdomyosarcoma cells to irradiation. *Frontiers in Cell and Developmental Biology.* *Front Cell Dev Biol.* 2023 Jan 23; 11:1061570. doi: 10.3389/fcell.2023.1061570 (article, PMID: 36755974).

8. Vaccaro S, Rossetti A, Porrizzo A, Camero S, Cassandri M, Pomella S, Tomaciello M, Macioce G, Pedini F, Barillari G, Marchese C, Rota R, Cenci G, Tombolini M, Newman RA, Yang P, Codenotti S, Fanzani A, Megiorni F, Festuccia C, Minniti G, Gravina GL, Vulcano F, Milazzo L, Marampon F. The Botanical Drug PBI-05204, a Supercritical CO₂ Extract of Nerium Oleander, Sensitizes Alveolar and Embryonal Rhabdomyosarcoma to Radiotherapy in vitro and in vivo. *Frontiers in Pharmacology* 2022 (Research article): 13, 1071176 [10.3389/fphar.2022.1071176].
9. Pomella S, Porrizzo A, Cassandri M, Megiorni F, Rota R, Milazzo L, Vulcano F, Barillari G, Cenci G, Marchese C, Fanzani A, Marampon F. Translational Implications for Radiosensitizing Strategies in Rhabdomyosarcoma. *International Journal of Molecular Sciences* 2022 (review): 23(21), 13281 [10.3390/ijms232113281].
10. Lucarini V, Melaiu O, D'Amico S, Pastorino F, Tempora P, Scarsella M, Pezzullo M, De Ninno A, D'Oria V, Cilli M, Emionite L, Infante P, Di Marcotullio L, De Ioris MA, Barillari G, Alaggio R, Businaro L, Ponzoni M, Locatelli F, Fruci D. Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma. *Journal of Experimental & Clinical Cancer Research* 2022: 41(1), 326 [10.1186/s13046-022-02525-9].
11. Camero S, Cassandri M, Pomella S, Milazzo L, Vulcano F, Porrizzo A, Barillari G, Marchese C, Codenotti S, Tomaciello M, Rota R, Fanzani A, Megiorni F, Marampon F. Radioresistance in rhabdomyosarcomas: Much more than a question of dose. *Front Oncol.* 2022 Sep 29; 12:1016894. (review, doi: 10.3389/fonc.2022.1016894. PMID: 36248991; PMCID: PMC9559533).
12. Barillari G, Melaiu O, Gargari M, Pomella S, Bei R, Campanella V. The Multiple Roles of CD147 in the Development and Progression of Oral Squamous Cell Carcinoma: An Overview. *Int J Mol Sci* 2022; 23: 8336. (review, doi: 10.3390/ijms23158336. PMID: 35955471; PMCID: PMC9369056).
13. Bei R, Benvenuto M, Focaccetti C, Fazi S, Moretti M, Nardozi D, Angiolini V, Ciuffa S, Cifaldi L, Carrano R, Palumbo C, Miele MT, Bei R, Barillari G, Manzari V, De Smaele E, Modesti A, Masuelli L. Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo. *J Transl Med* 2022; 20: 286. (article, doi: 10.1186/s12967-022-03490-9. PMID: 35752861; PMCID: PMC9233819).
14. Barillari G, Bei R, Manzari V, Modesti A. Infection by High-Risk Human Papillomaviruses, Epithelial-to-Mesenchymal Transition and Squamous Pre-Malignant or Malignant Lesions of the Uterine Cervix: A Series of Chained Events? *Int J Mol Sci* 2021; 22: 13543. doi: 10.3390/ijms222413543. PMID: 34948338; PMCID: PMC8703928 (review, ISSN 14220067, publisher: MDPI).
15. Benvenuto M, Ciuffa S, Focaccetti C, Sbardella D, Fazi S, Scimeca M, Tundo GR, Barillari G, Segni M, Bonanno E, Manzari V, Modesti A, Masuelli L, Coletta M, Bei R. Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells. *Sci Rep* 2021; 11: 19051 (article, doi: 10.1038/s41598-021-98450-6. PMID: 34561494; PMCID: PMC8463577).
16. Cafaro A, Barillari G, Moretti S, Palladino C, Tripiciano A, Falchi M, Picconi O, Pavone Cossut MR, Campagna M, Arancio A, Sgadari C, Andreini C, Banci L, Monini P, Ensoli B. HIV-1 Tat Protein Enters Dysfunctional Endothelial Cells via Integrins and Renders Them Permissive to Virus Replication. *Int J Mol Sci* 2021; 22: 317-340. <https://doi.org/10.3390/ijms22010317> (article, ISSN 14220067, publisher: MDPI).
17. Qiu Y, Maione F, Capano S, Meda C, Picconi O, Brundu S, Pisacane A, Sapino A, Palladino C, Barillari G, Monini P, Bussolino F, Ensoli B, Sgadari C, Giraudo E. HIV-protease inhibitors block HPV16-induced murine cervical carcinoma and promote vessel normalization in association with MMP-9 inhibition and TIMP-3 induction. *Mol Cancer*

- Ther 2020; 19: 2476-2489. doi: 10.1158/1535-7163.MCT-20-0055 (article, ISSN 15357163, publisher: American Association for Cancer Research).
18. Barillari G. The Impact of Matrix Metalloproteinase-9 on the Sequential Steps of the Metastatic Process. *Int J Mol Sci* 2020; 21: 4526. doi: 10.3390/ijms21124526 (review, ISSN 14220067, publisher: MDPI).
 19. Barillari G. The Anti-Angiogenic Effects of Anti-Human Immunodeficiency Virus Drugs. *Front Oncol* 2020; 10:806. doi: 10.3389/fonc.2020.00806 (review, ISSN 2234943, publisher: Frontiers Media).
 20. Barillari G, Monini P, Sgadari, Ensoli B. The impact of human papilloma viruses, matrix metalloproteinases and HIV protease inhibitors on the onset and progression of uterine cervix epithelial tumors: a review of preclinical and clinical studies. *International Journal of Molecular Sciences* 2018; 19: 1418-1442, doi: 10.3390/ijms19051418 (review, ISSN 14220067, publisher: MDPI).
 21. Bacigalupo I, Palladino C, Leone P, Toschi E, Sgadari C, Ensoli B, Barillari G. Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells. *Oncology Letters* 13: 2903-2908, 2017. doi: 10.3892/ol.2017.5835 (article, ISSN 1792-1074, publisher: Spandidos Publications).
 22. Barillari G, Palladino C, Bacigalupo I, Leone P, Falchi M, Ensoli B. Entrance of the Tat protein of HIV-1 into human uterine cervical carcinoma cells causes up-regulation of HPV-E6 expression and a decrease in p53 protein levels. *Oncology Letters*, 12: 2389-2394, 2016 (article, ISSN 1792-1074, publisher Spandidos Publications).
 23. Barillari G, Iovane A, Bacigalupo I, Labbaye C, Chiozzini C, Sernicola L, Quaranta MT, Falchi M, Sgadari C, Ensoli B. The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells. *Angiogenesis*, 7 (4): 831-8, 2014. doi: 10.1007/s10456-014-9430-9 (article, ISSN 0969 0969-6970, publisher: Springer).
 24. Bucchi L, Cortecchia S, Galanti G, Sgadari C, Costa S, De Lillo M, Caparra L, Barillari G, Monini P, Nannini R, and Ensoli B. Follow-up study of patients with cervical intraepithelial neoplasia grade 1 overexpressing p16ink4a. *International Journal of Gynecological Cancer* 23 (9):1663-9, 2013 (article, ISSN 1048-891X, publisher: Lippincott, Williams & Wilkins).
 25. Barillari G, Iovane A, Bacigalupo I, Palladino C, Bellino S, Leone P, Monini P, and Ensoli B. Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. *AIDS* 26 (8): 909-919, 2012. doi: 10.1097/QAD.0b013e328351f7 a5 (article, ISSN 0269-9370, publisher: Lippincott, Williams & Wilkins).
 26. Sgadari C, Bacigalupo I, Barillari G, Ensoli B. Pharmacological management of Kaposi's sarcoma. *Expert Opinion on Pharmacotherapy* 12 (11): 1669-1690, 2011 (review, ISSN 1465-6566, publisher: Informa Healthcare).
 27. Sgadari C, Barillari G, Palladino C, Bellino S, Taddeo B, Toschi E, Ensoli B. Fibroblast growth factor-2 and the HIV-1 Tat protein synergize in promoting Bcl-2 expression and preventing endothelial cell apoptosis: implications for the pathogenesis of AIDS-associated Kaposi's sarcoma. *International Journal of Vascular Medicine e-PUB DOI* 10.1155/2011/452729, 2011 (article, ISSN 2090-2824, publisher: Hindawi Publication Corporation).
 28. Toschi E, Sgadari C, Malavasi L, Bacigalupo I, Chiozzini C, Carlei D, Compagnoni D, Bellino S, Bugarini R, Falchi M, Palladino C, Leone P, Barillari G, Monini P, Ensoli B. Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via proteasome-independent block of angiogenesis and matrix metalloproteinases. *International Journal of Cancer*, 128: 82-93, 2011 (article, ISSN 0020-7136, publisher: Wiley-Liss).

29. Barillari G, Franzese O, Comandini A, Bonmassar E, Ensoli B. Spindle cells from AIDS-associated Kaposi's sarcoma (KS) lesions express telomerase activity that is enhanced by KS progression factors. *Oncology Reports*, 24 (1): 219-223, 2010 (article, ISSN 1021-335X, publisher: Spandidos Publications).
30. Albonici L, Sorge RP, Santeusano G, Garofano P, Manzari V, Barillari G. Correlation between pathological data and the RNA expression of p53 or p53-targeted genes in primary invasive ductal breast carcinomas: a preliminary study. *Oncology Reports*, 23: 1119-1123, 2010 (article, ISSN 1021-335X, publisher: Spandidos Publications).
31. Barillari G, Franzese O, Iovane A and Ensoli B. Spindle cells from Acquired Immune Deficiency Syndrome (AIDS)-associated Kaposi's sarcoma (KS) lesions express telomerase activity directly relating to the RNA levels of fibroblast growth factor (FGF)-2. *International Journal of Cancer*, 127: 2487-2489, 2010 (letter, ISSN 0020-7136, publisher: Wiley-Liss).
32. Barillari G, Iovane A, Bonuglia M, Albonici L, Garofano P, Di Campi E, Falchi M, Condò I, Manzari V, Ensoli B. Fibroblast growth factor-2 transiently activates the p53 oncosuppressor protein in human primary vascular smooth muscle cells: implications for atherogenesis. *Atherosclerosis*, 210 (2): 400-406, 2010 (article, ISSN 0021-9150, publisher: Elsevier).
33. Nappi F, Chiozzini C, Bordignon V, Borsetti A, Bellino S, Cippitelli M, Barillari G, Caputo A, Tyagi M, Giacca M, Ensoli B. Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation independent mechanism which requires binding of Tat to viral particles. *Journal of Gene Medicine*, 11 (11): 955-965, 2009 (article, ISSN 1099-498X, publisher: John Wiley & Sons).
34. Fanales-Belasio E, Moretti S, Fiorelli V, Tripiciano A, Pavone-Cossut MR, Scoglio A, Colacchi B, Nappi F, Macchia I, Bellino S, Francavilla V, Caputo A, Barillari G, Magnani M, Laguardia ME, Cafaro A, Titti F, Monini P, Ensoli F, Ensoli B. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. *Journal of Immunology* 182 (5): 2888-2897, 2009 (article, ISSN 0022-1767, publisher: American Association of Immunologists).
35. Barillari G, Toschi E, Sgadari C, Monini P, Ensoli B. The formation of new blood vessels in Kaposi's sarcoma. In *The Research Signpost (Kaposi's sarcoma: a model of oncogenesis)*; Stebbing J, Pantanowitz L, and Dezube BJ editors, Tufts Medical School, Boston (MA, USA), chapter 6, pp 101-122, 2009 (book chapter, ISBN 978-81-308-0380-7, publisher: Research Signpost, USA).
36. Monini P, Sgadari C, Grosso MG, Bellino S, Di Biagio A, Toschi E, Bacigalupo I, Sabbatucci M, Cencioni G, Salvi E, Leone P, Ensoli B, Barillari G, Moracci G, Carratelli L, Gatti G, Brambilla L, Brambati M, Ferrucci S, De Pità O, Pilla MA, Di Carlo A, Giuliani M, Cottoni F, Cuccuru MA, Calvieri S, Clerico R, Potenza C, Tirelli U, Simonelli C, Martellotta F, Strumia R, Borghi A, Del Giacco S, Moi L, Piludu G, Sirianni MC, Campagna M, Sarmati L, Andreoni M, Bianchini G, Sheldon J, Milzer J, Schulz T. Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. *AIDS* 23 (4): 534-538, 2009 (article, ISSN 0269-9370, publisher: Lippincott, Williams & Wilkins).
37. Monini P, Toschi E, Sgadari C, Bacigalupo I, Palladino C, Carlei D, Barillari G, and Ensoli B. The use of HAART for biological tumour therapy. *Journal of HIV Therapy*, 11 (3): 53-56, 2006 (review, ISSN 1462-0308, publisher: Mediscript).
38. Toschi E, Bacigalupo I, Strippoli R, Cereseto A, Falchi M, Chiozzini C, Nappi F, Sgadari C, Barillari G, Maniero F, and Ensoli B. HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway. *Molecular Biology of the Cell*, 17 (4): 1985-1994, 2006 (article, ISSN 1059-1524, publisher: American Society for Cell Biology).

39. Monini P, Sgadari C, Toschi E, Barillari G and Ensoli B. Antitumour effects of antiretroviral therapy. *Nature Reviews. Cancer*, 4: 861-875, 2004 (review, ISSN 1474-175X, publisher: Nature Publishing Group).
40. Sgadari C, Monini P, Barillari G and Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumor growth. *Lancet Oncology*, 4: 537-547, 2003 (review, ISSN 1470-2045, publisher: Lancet Publishing Group).
41. Barillari G, Sgadari C, Toschi E, Monini P and Ensoli B. HIV protease inhibitors as new treatment options for Kaposi's sarcoma. *Drug Resistance Updates*, 6 (4): 173-181, 2003 (review, ISSN 1368-7646, publisher: Churchill Livingstone).
42. Grosso G, Sgadari C, Barillari G, Toschi E, Bacigalupo I, Carlei D, Palladino C, Baccarini S, Malavasi L, Moracci G, Leone P, Chiozzini C, Monini P, Ensoli B. HIV protease inhibitors for the treatment of Kaposi's sarcoma. *Recenti Progressi in Medicina* 94: 69-74, 2003 (review, ISSN 0034-1193, publisher: Il Pensiero Scientifico editore).
43. Monini P, Sgadari C, Barillari G, and Ensoli B. The HIV protease inhibitors: anti-retroviral agents with anti-inflammatory, anti-angiogenic and anti-tumor activity. *The Journal of Antimicrobial Chemotherapy* 51 (2): 207-211, 2003 (review, ISSN 0305-7453, publisher: Oxford University Press).
44. Ensoli B, Sgadari C, Barillari G and Monini P. The fibroblast growth factors. *The Cytokine Handbook (IV Edition)*: 747-781. Thomson AW & Lotze MT editors, Elsevier Science Ltd. Publisher, London 2003 (book chapter, ISBN 0-12-689663-1, publisher: Elsevier Science).
45. Toschi E, Monini P, Barillari G, Bacigalupo I, Palladino C, Baccarini S, Carlei D, Grosso G, Sirianni MC and Ensoli B. Treatment of Kaposi's sarcoma: an update. *Anticancer Drugs*, 13: 977-987, 2002 (review, ISSN 0959-4973, publisher: Lippincott, Williams & Wilkins).
46. Barillari G and Ensoli B. Angiogenic effects of extracellular HIV-1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. *Clinical Microbiology Reviews*, 15 (2): 310-326, 2002 (review, ISSN0893-8512, publisher: American Society of Microbiology).
47. Ciafrè SA, Barillari G, Bongiorno Borbone L, Wannenes F, Izquierdo M and Farace MG. A tricistronic retroviral vector expressing natural antiangiogenic factors inhibits angiogenesis in vitro. *Gene Therapy*, 9: 297-302, 2002 (article, ISSN 0969-7128, publisher: Nature Publishing Group).
48. Fanales-Belasio E, Moretti S, Nappi F, Barillari G, Micheletti F, Cafaro A and Ensoli B. Native HIV-1 Tat protein is selectively taken up by monocyte-derived dendritic cells and induces their maturation, Th-1 cytokine production and antigen presenting function. *Journal of Immunology*, 168: 197-206, 2002 (article, ISSN 0022-1767, publisher: American Society of Immunologists).
49. Sgadari C, Carlei D, Barillari G et al. HIV protease inhibitors block angiogenesis and promote regression of Kaposi's sarcoma in the nude mouse model. *Clinical and Experimental Pharmacology and Physiology* 29 (8): 94-95, 2002 (abstract, ISSN: 0305-1870, publisher: Wiley-Blackwell).
50. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P and Ensoli B. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi's sarcoma. *Nature Medicine*, 8 (3): 225-232, 2002 (article, ISSN 1078-8956, publisher: Nature Publishing Group).
51. Toschi E, Barillari G, Sgadari S, Bacigalupo I, Cereseto A, Carlei D, Palladino C, Zietz C, Leone P, Sturzl M, Buttò S, Cafaro A, Monini P and Ensoli B. Activation of MMP-2 and MT1-MMP in endothelial cells and induction of vascular permeability in vivo by the HIV-1 Tat protein and basic fibroblast growth factor. *Molecular Biology of the Cell*, 12: 2934-2946, 2001 (article, ISSN 1059-1524, publisher: American Society for Cell Biology).

52. Guenzi E, Cornali E, Topolt K, Martellato C, Zietz C, Kremmer E, Nappi F, Schwemmle M, Hohenadl C, Jorg A, Matzen K, Barillari G, Tschachler E, Monini P, Ensoli B and Sturzl M. The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. *The EMBO Journal*, 20: 5568-5577, 2001 (article, ISSN 0261-4189, publisher: Wiley Blackwell).
53. Ensoli B, Sgadari C, Barillari G, Sirianni MC, Sturzl M, Monini P. Biology of Kaposi's sarcoma. *European Journal of Cancer*, 37: 1251-1269, 2001 (review, ISSN 0959-8049, publisher: Elsevier Science).
54. Bussolino F, Mitola S, Serini G, Barillari G, Ensoli B. Interactions between endothelial cells and HIV-1. *The International Journal of Biochemistry and Cell Biology*, 33: 371-390, 2001 (review, ISSN 1357-2725, publisher: Elsevier).
55. Barillari G, Albonici L, Incerpi S, Bogetto L, Pistrutto G, Volpi A, Ensoli B and Manzari V. Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing $\alpha 5\beta 1$ integrin expression and function. *Atherosclerosis*, 154: 377-385, 2001 (article, ISSN 0021-9150, publisher: Elsevier).
56. Sgadari C, Toschi E, Palladino C, Barillari G, Carlei D, Cereseto A, Ciccolella C, Yarchoan R, Monini P, Sturzl M, Ensoli B. Mechanism of paclitaxel activity in Kaposi's sarcoma. *Journal of Immunology*, 165: 509-517, 2000 (article, ISSN 0022-1767, publisher: American Association of Immunologists).
57. Ciafrè SA, Barillari G, Wannenes F, Bongiorno Borbone L, and Farace MG. Multicistronic antiangiogenic retroviral vectors for the gene therapy of malignant brain tumors. *Cancer Gene Therapy*, 7 (10): 1395-1396, 2000 (abstract, ISSN: 0929-1903, publisher: Nature Publishing Group).
58. Barillari G, Sgadari C, Palladino C, Gendelman R, Caputo A, Bohan-Morris C, Nair BC, Markham P, Sturzl M and Ensoli B. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of bFGF and the $\alpha \beta 3$ integrin that are required for Tat activity. *Journal of Immunology* 163: 1929-1935, 1999 (article, ISSN 0022-1767, publisher: American Association of Immunologists).
59. Barillari G, Sgadari C, Fiorelli V, Samaniego F, Colombini S, Manzari V, Modesti A, Nair BC, Cafaro A, Sturzl M and Ensoli B. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the $\alpha 5\beta 1$ and $\alpha \beta 3$ integrins and by mobilizing sequestered basic fibroblast growth factor. *BLOOD* 94: 663-672, 1999 (article, ISSN 0006-4971, publisher: American Society for Haematology).
60. Fiorelli V, Barillari G, Sgadari C, Toschi E, Monini P, Sturzl M and Ensoli B. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to HIV-1 Tat. *Journal of Immunology* 162: 1165-1170, 1999 (article, ISSN 0022-1767, publisher: American Association of Immunologists).
61. Pica F, Volpi A, Barillari G, Fraschetti M, Franzese O, Vullo V and Garaci E. Detection of high NGF serum levels in AIDS-related and -unrelated KS patients. *AIDS* 12: 7329-7334, 1998 (article, ISSN 0269-9370, publisher: Lippincott, Williams & Wilkins).
62. Barillari G, Albonici L, Franzese O, Modesti A, Liberati F, Barillari P, Ensoli B, Manzari V and Santeusano G. The basic residues of PlGF-2 retrieve sequestered angiogenic factors into a soluble form. *The American Journal of Pathology*, 152: 1161-1166, 1998 (article, ISSN 0002-9440, publisher: Elsevier).
63. Barillari G, Albonici L, Manzari V, Liberati F, Iafrate E and Santeusano G. Transcription of placenta growth factor type-2 correlates with intratumoral microvessel density in breast carcinomas. *Clinical and Experimental Pathology* 48: 296, 1998 (abstract, ISSN 1292-7953, publisher: Expansion Scientifique).
64. Barillari G, Albonici L, Manzari V. Basic FGF modifies the interactions between endothelial cells and fibronectin: implications for the progression of AIDS-associated

- Kaposi's sarcoma. *Archives of STD/HIV Research*, 11 (1): 23-37, 1997 (article, ISSN 1071-0906, publisher: Reproductive Health Center).
65. Barillari G, Fiorelli V, Gendelman R. HIV-1 Tat protein enhances angiogenesis and Kaposi's sarcoma development triggered by inflammatory cytokines and bFGF by engaging the $\alpha\beta 3$ integrin. *AIDS Research and Human Retroviruses*, 14: 68, 1997 (abstract, ISSN 0889-2229, publisher: Mary Ann Liebert).
 66. Barillari G, Albonici L and Manzari V. Another mechanism involved in AIDS-KS progression. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 55, 1996 (abstract, ISSN: 1077-9450, publisher: Lippincott Williams & Wilkins)
 67. Franzese O, Minchella I, Pistrutto G, Barillari G, Bonmassar E and D'Onofrio C. PDGF-B as a possible growth factor in AIDS-KS. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 24, 1996 (abstract, ISSN: 1077-9450, publisher: Lippincott Williams & Wilkins).
 68. Albini A, Barillari G, Benelli R, Gallo RC, and Ensoli B. Angiogenic properties of Human Immunodeficiency Virus type 1 Tat protein. *Proceedings of the National Academy of Sciences of the United States of America (PNAS)* 92: 4838-4842, 1995 (article, ISSN 0027-8424, publisher: National Academy of Sciences).
 69. Ensoli B, Barillari G, Fiorelli V, Samaniego F, Gendelman R, Chang HC, Colombini S, Watanabe Y, Kao V, Nair BC. HIV-1 Tat protein mimics the effect of extracellular matrix (ECM) protein on vascular cell growth and angiogenesis: implications for AIDS-Kaposi's sarcoma (AIDS-KS) pathogenesis. *AIDS Research and Human Retroviruses* 11 (1): S75, 1995 (abstract, ISSN 0889-2229, publisher: Mary Ann Liebert).
 70. Ensoli B, Barillari G, Fiorelli V, Gallo RC. Cooperation of HIV-1 Tat protein, inflammatory cytokines or bFGF in the pathogenesis of AIDS-Kaposi's sarcoma. *AIDS Research and Human Retroviruses*. 10 (1): 53, 1994 (abstract, ISSN 0889-2229, publisher: Mary Ann Liebert).
 71. Ensoli B, Markham P, Kao V, Barillari G, Fiorelli V, Gendelman R, Raffeld M, Zon G, and Gallo RC. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis and lesion formation in nude mice by antisense oligonucleotides targeting basic fibroblast growth factor. *Journal of Clinical Investigation*, 94: 1736-1746, 1994 (article, ISSN 0021-9738, publisher: American Society for Clinical Investigation).
 72. Ensoli B, Barillari G, Fiorelli V, Gallo RC. Cooperation of HIV-1 Tat protein, inflammatory cytokines or bFGF in the pathogenesis of AIDS-Kaposi's sarcoma. *AIDS Research and Human Retroviruses* 10 (1): 53, 1994 (abstract, ISSN 0889-2229, publisher: Mary Ann Liebert).
 73. Holmes AM, Barillari G, Gallo RC, Ensoli B. Integrin-mediated uptake of HIV-1 Tat protein by cytokine-activated endothelial cells. *AIDS Research and Human Retroviruses* 10 (1): S53, 1994 (abstract, ISSN 0889-2229, publisher: Mary Ann Liebert).
 74. Ensoli B, Markham P, Kao V, Raffeld M, Gendelman R, Barillari G. Basic FGF induces lesions in mice resembling KS, and antisense oligonucleotides against this cytokine inhibit the growth and angiogenic activity of KS spindle cells. *Journal of Cellular Biochemistry* 18: 327, 1994 (abstract, ISSN: 0730-2312, publisher: Wiley-Liss).
 75. Barillari G, Gendelman R, Gallo RC, and Ensoli B. The Tat protein of HIV-1, a growth factor for AIDS-Kaposi's sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD sequence. *Proceedings of the National Academy of Sciences of the United States of America (USA)* 90: 7941-7945, 1993 (article, ISSN 0027-8424, publisher: National Academy of Sciences).
 76. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, and Gallo RC. Release, uptake and effects of extracellular Human Immunodeficiency Virus type-1 Tat protein on cell growth and viral transactivation. *Journal of Virology* 67: 277-287, 1993 (article, ISSN 0022-538X, publisher: American Society for Microbiology).

77. Barillari G, Holmes A, Gendelman R, Buonaguro L, Gallo RC, Ensoli B. The RGD motif and the integrin receptors are involved in the vascular cell growth and adhesion properties of extracellular HIV-1 Tat protein. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology* 6 (6): 688, 1993 (abstract, ISSN 1077-9450, publisher: Lippincott, Williams & Wilkins).
78. Fiorelli V, Barillari G, Gallo RC, and Ensoli B. Biological properties of Human Immunodeficiency Virus type-1 Tat protein: angiogenic effects and adhesive interactions of extracellular Tat. In K.T. Preissner, S. Rosenblatt, C. Kost, J. Wegerhoff and D.F. Mosher (eds): *Biology of vitronectins and their receptors*: 351-360, 1993 (book chapter, publisher: Excerpta Medica, Amsterdam).
79. Buonaguro L, Barillari G, Chang HK, Kao V, Gallo RC, Ensoli B. Cytokine activation during HIV-1 infection: induction of tumor necrosis factor (TNF) gene expression by HIV-1 Tat. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 6 (6): 718, 1993 (abstract, ISSN: 1077-9450, publisher: Lippincott Williams & Wilkins).
80. Barillari G, Buonaguro L, Fiorelli V, Ensoli B. Immune activation, rather than immune deficiency, cooperates with HIV infection in the development of AIDS-associated Kaposi's sarcoma. *AIDS Research and Human Retroviruses* 6 (6): 872, 1993 (abstract, ISSN 0889-2229, publisher: Mary Ann Liebert).
81. Ensoli B, Markham P, Raffeld M, Barillari G. Basic fibroblast growth factor mediates the growth and angiogenic activity of AIDS-Kaposi's sarcoma (KS)-derived spindle cells and synergises with HIV-1 Tat protein in inducing KS-like lesions in mice. *BLOOD* 82: 453, 1993 (abstract, ISSN 0006-4971, publisher: American Society for Haematology).
82. Ensoli B, Albini A, Barillari G. Release and angiogenic properties of extracellular HIV-1 Tat protein. *AIDS Research and Human Retroviruses* 6: 688, 1993 (abstract, ISSN 0889-2229, publisher: Mary Ann Liebert).
83. Barillari G, Manzari V. Il sarcoma di Kaposi associato alla Sindrome da Immunodeficienza Acquisita. In P. Anello (ed.) 3: 4-8, 1993 (book chapter, publisher: Monos Omnia, Palermo).
84. Ensoli B, Buonaguro L, Barillari G. Release-uptake of HIV-1 Tat and mechanisms of Tat-induced paracrine biological effects. *AIDS Research and Human Retroviruses* 872, 1992 (abstract, ISSN 0889-2229, publisher: Mary Ann Liebert).
85. Ensoli B, Barillari G, Buonaguro L. Role of cytokines from activated T cells and HIV-1 Tat protein in the pathogenesis of AIDS-associated Kaposi's sarcoma. *AIDS Research and Human Retroviruses* 8: 876, 1992 (abstract, ISSN 0889-2229, publisher: Mary Ann Liebert).
86. Buonaguro L, Chang HK, Bohan C, Barillari G. Tat, the transactivator gene of HIV-1, activates the expression of tumor necrosis factor-beta. *AIDS Research and Human Retroviruses* 8: 872, 1992 (abstract, ISSN 0889-2229, publisher: Mary Ann Liebert).
87. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan R, Wingfield P, Gallo RC. Release-uptake of HIV-1 Tat and mechanisms of Tat-induced paracrine biological effects (TAT domains and pathways for cell growth and transactivation activity). *AIDS Research and Human Retroviruses* 8 (5): 872, 1992 (abstract, ISSN 0889-2229, publisher: Mary Ann Liebert).
88. Barillari G, Crowley R, Gendelman R, Biberfeld P, Gallo RC, Ensoli B. Inflammatory cytokines increase mesenchymal cell growth and attachment induced by HIV-1 Tat protein and adhesion molecules: implications for AIDS-Kaposi's sarcoma pathogenesis. *AIDS Research and Human Retroviruses* 8 (5): 876, 1992 (abstract, ISSN 0889-2229, publisher: Mary Ann Liebert).
89. Barillari G, Buonaguro L, Fiorelli V, Hoffman J, Michaels F, Gallo RC, and Ensoli B. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. *Journal of Immunology* 149: 3727-3734, 1992 (article, ISSN 0022-1767, publisher: American Association of Immunologists).

90. Buonaguro L, Barillari G, Chang HK, Bohan CA, Morgan RA, Kao V, Gallo RC, and Ensoli B. Effects of HIV-1 Tat protein on the expression of inflammatory cytokines. *Journal of Virology* 66: 7159-7167, 1992 (article, ISSN 0022-538X, publisher: American Society for Microbiology).
91. Ensoli B, Barillari G, and Gallo RC. Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma. In Moller, G. (Ed.) *Immunological Reviews* 127: 147-155, 1992 (review, ISSN 0105-2896, publisher: Munksgaard, Copenhagen).
92. Ensoli B, Barillari G, and Gallo RC. Pathogenesis of AIDS-associated Kaposi's sarcoma. *Haematology Oncology Clinics of North America* 5: 281-295, 1991 (review, ISSN 0889-8588, publisher: Saunders).
93. Ensoli B, Barillari G, Buonaguro L and Gallo RC. Molecular mechanisms in the pathogenesis of AIDS-associated Kaposi's sarcoma. *Advances in Experimental Medicine & Biology* 303: 27-38, 1991 (book chapter, ISSN 0065-2598, publisher: Kluwer Academic/Plenum).
94. Ensoli B, Barillari G, Buonaguro L, and Gallo RC. Pathogenesis of AIDS-associated Kaposi's sarcoma. In Atassi MZ (ed.) *Immunobiology of Proteins and Peptides*. *Immunobiology* 303: 27-38, 1991 (review, publisher: Plenum Press, New York).
95. Barillari G, Buonaguro L, Fiorelli V, Gallo RC and Ensoli B. Lymphokines released by activated or HTLV-infected T cells induce growth of normal mesenchymal cells and of cells derived from Kaposi's sarcoma lesions of AIDS patients. *Journal of Cellular Biochemistry* 15: 63, 1991 (abstract, ISSN: 0730-2312, publisher: Wiley-Liss).
96. Ensoli B, Barillari G, Buonaguro L, Chang HK and Gallo RC. Immune stimulation and HIV-1 infection have complementary effects in the induction and progression of AIDS-associated Kaposi's sarcoma via release of cytokines and Tat. *Journal of Cellular Biochemistry* 15: 249, 1991 (abstract, ISSN: 0730-2312, publisher: Wiley-Liss).
97. Ensoli B, Buonaguro L, Barillari G, Lusso P, Gallo RC. Role of HIV-1 TAT gene product and of cytokines released by activated immune cells in the pathogenesis of AIDS-associated Kaposi's sarcoma. *AIDS Research and Human Retroviruses* 7 (2): 217-218, 1991 (abstract, ISSN 0889-2229, publisher: Mary Ann Liebert).
98. Barillari G, Buonaguro L, Hoffmann J. Cytokines released by activated primary T cells stimulate the growth of AIDS-KS-derived cells and other cells of mesenchymal derivation. *AIDS Research and Human Retroviruses*: 217, 1991 (abstract, ISSN 0889-2229, publisher: Mary Ann Liebert).
99. Biberfeld P, Nakamura S, Ensoli B, Salahuddin SZ, Barillari G, Parravicini C, Gendelman R, Kaaya EE, and Gallo RC. Autocrine and paracrine mechanisms in the evolution of Kaposi's sarcoma (KS). In B. Westermarck, C. Besholtz and B. Hokfelt (eds): *Proc. Nordisk Insulin Symp. IV*: 277-280, 1990 (book chapter, publisher: Elsevier, Copenhagen).
100. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, and Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. *Nature* 344: 84-86, 1990 (article, ISSN 0028-0836, publisher: Nature Publishing Group).
101. Barillari G, Buonaguro L, Gallo RC, Ensoli B. Activated peripheral blood lymphocytes produce factors promoting the growth of spindle cells derived from AIDS-associated Kaposi's sarcoma. *Lymphokine Research* 9 (4): 582, 1990 (abstract, ISSN: 0277-6766, publisher: Mary Ann Liebert).
102. Barillari G, French D, Barillari P, De Antoni E, Frati L, and Manzari V. Cellular oncogenes amplification and over-expression in human colorectal carcinomas. *Advances in Experimental Medicine & Biology* 2: 193-200, 1989 (book chapter, ISSN 0065-2598, publisher: Kluwer Academic/Plenum).
103. Barillari P, Aurello P, De Angelis R, Gozzo P, Lolli E, Indinnimeo EM, Brozzetti S, Ramacciato G, Valabrega S, Barillari G. Tissue CEA as prognostic indicator in a series of

- 31 cases of gastric cancer. *The Italian Journal of Surgical Sciences* 18 (3): 237-41, 1988 (article, ISSN 0392-3525, publisher: Masson, Milan, Italy).
104. Manzari V, Gismondi A, Barillari G, Morrone S, Modesti A, Albonici L, De Marchis L, Fazio VM, Gradilone A, Zani M, Frati L, and Santoni A. HTLV-V: a new human retrovirus isolated in a TAC-negative T-cell lymphoma/leukemia. *Science* 238: 1581-1583, 1987 (article, ISSN 0036-8075, publisher: American Association for the Advancement in Science).
 105. Manzari V, Barillari G, Albonici L, De Marchis L, and Frati L. Human T-lymphotropic infection in Italy. In *Normal and Neoplastic Blood Cells: from genes to therapy*. *Annals of the New York Academy of Sciences* 511: 401-405, 1987 (review, ISSN 0077-8923, publisher: New York Academy of Sciences).
 106. Gismondi A, Barillari G, Morrone S, Modesti A, De Marchis L, Albonici L, Giuffrida A, Frati L, Santoni A, Manzari V. Stabilizzazione di una linea cellulare infettata da un nuovo membro della famiglia degli HTLV. *Immunologia Clinica IV* (2): 119-124, 1987 (book chapter, NLM ID 8813019, publisher: Masson, Milan, Italy).
 107. Barillari P, Leuzzi R, Aurello G, Ramacciato G, Valabrega S, De Angelis R, Cecere A, Indinnimeo M, Gozzo P, Virno VA, Barillari G. Tissue CEA as prognostic indicator in a series of 44 cases of colorectal cancer. *The Italian Journal of Surgical Sciences* 17 (4): 301-304, 1987 (article, ISSN 0392-3525, publisher: Masson, Milan, Italy).
 108. Collalti E, Barillari G, Albonici L, Santoni A, Frati L, Manzari V. Human T-lymphotropic retroviruses: a new member of the family. *Archives of AIDS Research* 1: 144, 1987 (abstract, ISSN: 0899-4811, publisher: Reproductive Health Center).
 109. Manzari V, Barillari G, Albonici L, Marchei P, Cifaldi L, Frati L. A new member of the HTLVs family (HTLV-V) in A. Visconti e O.E. Varnier (eds): *AIDS e Retrovirus Umani*: 39-41, 1987 (book chapter, publisher: Associazione Microbiologi Clinici Italiani, Milan, Italy).
 110. Gradilone A, Zani M, Barillari G, Modesti M, Aglianò AM, Maiorano G, Ortona L, Frati L, and Manzari V. HTLV-I and HIV-1 infection in drug addicts in Italy. *The Lancet*: 753-754, 1986 (article, ISSN 0140-6736, publisher: Elsevier).
 111. Pandolfi F, Semenzato G, De Rossi G, Barillari G, Napolitano M, Trentin L, Martelli M, Gradilone A, Cafaro A, Mandelli F, and Aiuti F. La leucemia linfatica cronica dei linfociti T. *Annali Italiani di Medicina Interna*, 1: 9-16, 1986 (review, ISSN 0393-9340, publisher: Pozzi- CEPI-AIM Group).
 112. Pandolfi F, Manzari V, De Rossi G, Semenzato G, Lauria F, Liso V, Ranucci A, Pizzolo G, Barillari G, and Aiuti F. T-helper phenotype chronic lymphocytic leukaemia and "adult T-cell leukaemia" in Italy. *Endemic HTLV-I-related T-cell leukaemias in southern Europe*. *The Lancet* 2 (8456): 633-636, 1985 (article, ISSN 0140-6736, publisher: Elsevier).
 113. Manzari V, Gradilone A, Barillari G, Zani M, Collalti E, Pandolfi F, De Rossi G, Liso V, Babbo P, Robert-Guroff M, and Frati L. HTLV-I is endemic in Southern Italy: detection of the first infectious cluster in a white population. *International Journal of Cancer* 36: 557-559, 1985 (article, ISSN 0020-7136, publisher: Wiley-Liss).
 114. Manzari V, Fazio VM, Gradilone A, Barillari G, and Frati L. Diffusion in Italy of Human T-cell Leukemia Virus I (HTLV-I): molecular epidemiology. *Peschle C and Rizzoli C (eds). New Trends in Experimental Haematology* 7: 262-266, 1984 (review, publisher: ARES Serono Symposia, Rome, Italy).